Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays

Annals of Anatomy

Volumn 192, Issue 3, 2010, Pages 133-138

  Airley, Rachel ^a   Evans, Andrew ^b   Mobasheri, Ali ^c   Hewitt, Stephen M ^d  

^a UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Expression pattern; Glut 1; Hypoxia; Tissue microarray; Tumors

Indexed keywords

GLUCOSE TRANSPORTER 1;

ARTICLE; BREAST ADENOCARCINOMA; BRONCHIOALVEOLAR ADENOCARCINOMA; CANCER TISSUE; CENTRAL NERVOUS SYSTEM; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOTHELIUM; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOMA; MELANOMA; OVARY TUMOR; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SPLEEN; TISSUE MICROARRAY; TONGUE;

ANOXIA; BIOLOGICAL MARKERS; BREAST NEOPLASMS; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NECROSIS; NEOPLASMS; ORGAN SPECIFICITY; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; REFERENCE VALUES;

EID: 77952741529     PISSN: 09409602     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.aanat.2010.03.001     Document Type: Article

References (62)

1. Ahmed N., Berridge M.V. Regulation of glucose transport by interleukin-3 in growth factor-dependent and oncogene-transformed bone marrow-derived cell lines. Leuk. Res. 1997, 21:609-618.
2. Airley R., Loncaster J., Davidson S., Bromley M., Roberts S., Patterson A., Hunter R., Stratford I., West C. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. Cancer Res. 2001, 7:928-934.
3. Airley R.E., Loncaster J., Raleigh J.A., Harris A.L., Davidson S.E., Hunter R.D., West C.M., Stratford I.J. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int. J. Cancer. 2003, 104:85-91.
4. Airley R.E., Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007, 53:233-256.
5. Airley R.E., Phillips R.M., Evans A.E., Double J., Burger A.M., Feibig H.H., West C.M., Stratford I.J. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. Int. J. Oncol. 2005, 26:1477-1484.
6. Albertella M.R., Loadman P.M., Jones P.H., Phillips R.M., Rampling R., Burnet N., Alcock C., Anthoney A., Vjaters E., Dunk C.R., Harris P.A., Wong A., Lalani A.S., Twelves C.J. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin. Cancer Res. 2008, 14:1096-1104.
7. Amann T., Maegdefrau U., Hartmann A., Agaimy A., Marienhagen J., Weiss T.S., Stoeltzing O., Warnecke C., Scholmerich J., Oefner P.J., Kreutz M., Bosserhoff A.K., Hellerbrand C. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am. J. Pathol. 2009, 174:1544-1552.
8. Baron-Delage S., Mahraoui L., Cadoret A., Veissiere D., Taillemite J.L., Chastre E., Gespach C., Zweibaum A., Capeau J., Brot-Laroche E., Cherqui G. Deregulation of hexose transporter expression in Caco-2 cells by ras and polyoma middle T oncogenes. Am. J. Physiol. 1996, 270:G314-G323.
9. Behrooz A., Ismail-Beigi F. J. Biol. Chem. 1997, 272:5555-5562.
10. Binder C., Binder L., Marx D., Schauer A., Hiddemann W. Deregulated simultaneous expression of multiple glucose transporter isoforms in malignant cells and tissues. Anticancer Res. 1997, 17:4299-4304.
11. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996, 56:941-943.
12. Brown R.S., Wahl R.L. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993, 72:2979-2985.
13. Cantuaria G., Magalhaes A., Penalver M., Angioli R., Braunschweiger P., Gomez-Marin O., Kanhoush R., Gomez-Fernandez C., Nadji M. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol. Oncol. 2000, 79:33-37.
14. Chen C., Pore N., Behrooz A., Ismail-Beigi F., Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 2001, 276:9519-9525.
15. Chung F.Y., Huang M.Y., Yeh C.S., Chang H.J., Cheng T.L., Yen L.C., Wang J.Y., Lin S.R. GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer. 2009, 9:241.
16. Cooper R., Sarioglu S., Sokmen S., Fuzun M., Kupelioglu A., Valentine H., Gorken I.B., Airley R., West C. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. Br. J. Cancer 2003, 89:870-876.
17. Denekamp J., Dasu A. Inducible repair and the two forms of tumour hypoxia-time for a paradigm shift. Acta Oncol. 1999, 38:903-918.
18. Fogt F., Wellmann A., Urbanski S.J., Noffsinger A., Poremba C., Zimmerman R.L., Alsaigh N. Glut-1 expression in dysplastic and regenerative lesions of the colon. Int. J. Mol. Med. 2001, 7:615-619.
19. Furudoi A., Tanaka S., Haruma K., Yoshihara M., Sumii K., Kajiyama G., Shimamoto F. Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 2001, 60:162-169.
20. Gatenby R.A., Smallbone K., Maini P.K., Rose F., Averill J., Nagle R.B., Worrall L., Gillies R.J. Cellular adaptations to hypoxia and acidosis during somatic evolution of breast cancer. Br. J. Cancer 2007, 97:646-653.
21. Grover-McKay M., Walsh S.A., Seftor E.A., Thomas P.A., Hendrix M.J. Role for glucose transporter 1 protein in human breast cancer. Pathol. Oncol. Res. 1998, 4:115-120.
22. Hall Eric J. Radiobiology for the Radiologist 2000, Lippincott Williams & Wilkins, Philadelphia; London.
23. Haneda M., Koya D., Kikkawa R. Mesangial cell dysfunction as a pathogenesis of diabetic nephropathy. Contrib. Nephrol. 2001, 16-29.
24. Hatanaka M. Biochim. Biophys. Acta. 1974, 355:77-104.
25. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56:4509-4515.
26. Hoskin P.J., Sibtain A., Daley F.M., Wilson G.D. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br. J. Cancer 2003, 89:1290-1297.
27. Ito T., Noguchi Y., Satoh S., Hayashi H., Inayama Y., Kitamura H. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod. Pathol. 1998, 11:437-443.
28. Ito T., Noguchi Y., Udaka N., Kitamura H., Satoh S. Glucose transporter expression in developing fetal lungs and lung neoplasms. Histol. Histopathol. 1999, 14:895-904.
29. Joost H.G., Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol. Membr. Biol. 2001, 18:247-256.
30. Kitagawa K., Nishino H., Iwashima A. Analysis of hexose transport in untransformed and sarcoma virus-transformed mouse 3T3 cells by photoaffinity binding of cytochalasin B. Biochim. Biophys. Acta 1985, 821:63-66.
31. Klip A., Paquet M.R. Glucose transport and glucose transporters in muscle and their metabolic regulation. Diabetes Care. 1990, 13:228-243.
32. Manel N., Kinet S., Kim F.J., Taylor N., Sitbon M., Battini J.L. [GLUT-1 is the receptor of retrovirus HTLV]. Med. Sci. (Paris). 2004, 20:277-279.
33. Mayer A., Hockel M., Wree A., Vaupel P. Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. Clin. Cancer Res. 2005, 11:2768-2773.
34. McKeown S.R., Cowen R.L., Williams K.J. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol). 2007, 19:427-442.
35. Medina R.A., Owen G.I. Biol. Res. 2002, 35:9-26.
36. Mobasheri A., Airley R., Foster C.S., Schulze-Tanzil G., Shakibaei M. Post-genomic applications of tissue microarrays: basic research, prognostic oncology, clinical genomics and drug discovery. Histol. Histopathol. 2004, 19:325-335.
37. Mueckler M., Caruso C., Baldwin S.A., Panico M., Blench I., Morris H.R., Allard W.J., Lienhard G.E., Lodish H.F. Sequence and structure of a human glucose transporter. Science 1985, 229:941-945.
38. Niculescu-Duvaz I. Glufosfamide (Baxter Oncology). Curr. Opin. Investig. Drugs 2002, 3:1527-1532.
39. Oliver R.J., Woodwards R.T., Sloan P., Thakker N.S., Stratford I.J., Airley R.E. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur. J. Cancer. 2004, 40:503-507.
40. Osthus R.C., Shim H., Kim S., Li Q., Reddy R., Mukherjee M., Xu Y., Wonsey D., Lee L.A., Dang C.V. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 2000, 275:21797-21800.
41. Ozcan A., Shen S.S., Zhai Q.J., Truong L.D. Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am. J. Clin. Pathol. 2007, 128:245-254.
42. Pardridge W.M. Advances in cell biology of blood-brain barrier transport. Semin. Cell Biol. 1991, 2:419-426.
43. Potter C.P., Harris A.L. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br. J. Cancer. 2003, 89:2-7.
44. Rhoads D.B. Liver GLUT-1 expression: an enigma deepens. Hepatology. 1994, 19:540-542.
45. Rofstad E.K., Galappathi K., Mathiesen B., Ruud E.B. Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin. Cancer Res. 2007, 13:1971-1978.
46. Rogers S., Docherty S.E., Slavin J.L., Henderson M.A., Best J.D. Differential expression of GLUT12 in breast cancer and normal breast tissue. Cancer Lett. 2003, 193:225-233.
47. Rudlowski C., Becker A.J., Schroder W., Rath W., Buttner R., Moser M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am. J. Clin. Pathol. 2003, 120:691-698.
48. Sakashita M., Aoyama N., Minami R., Maekawa S., Kuroda K., Shirasaka D., Ichihara T., Kuroda Y., Maeda S., Kasuga M. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur. J. Cancer 2001, 37:204-209.
49. Schwartzenberg-Bar-Yoseph F., Armoni M., Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004, 64:2627-2633.
50. Seagroves T.N., Ryan H.E., Lu H., Wouters B.G., Knapp M., Thibault P., Laderoute K., Johnson R.S. Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol. Cell. Biol. 2001, 21:3436-3444.
51. Sridhar R., Stroude E.C., Inch W.R. Cytotoxicity of glucose analogues in V79 multicell spheroids. In Vitro 1979, 15:685-690.
52. Stewart G.D., Gray K., Pennington C.J., Edwards D.R., Riddick A.C., Ross J.A., Habib F.K. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol. Rep. 2008, 20:1561-1567.
53. Takata K. Glucose transporters in the transepithelial transport of glucose. J. Electron. Microsc. (Tokyo) 1996, 45:275-284.
54. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994, 13:139-168.
55. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am. J. Physiol. 1996, 270:G541-G553.
56. Wardell S.E., Ilkayeva O.R., Wieman H.L., Frigo D.E., Rathmell J.C., Newgard C.B., McDonnell D.P. Glucose metabolism as a target of histone deacetylase inhibitors. Mol. Endocrinol. 2009, 23:388-401.
57. Winter S.C., Buffa F.M., Silva P., Miller C., Valentine H.R., Turley H., Shah K.A., Cox G.J., Corbridge R.J., Homer J.J., Musgrove B., Slevin N., Sloan P., Price P., West C.M., Harris A.L. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res. 2007, 67:3441-3449.
58. Wood T.E., Dalili S., Simpson C.D., Hurren R., Mao X., Saiz F.S., Gronda M., Eberhard Y., Minden M.D., Bilan P.J., Klip A., Batey R.A., Schimmer A.D. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol. Cancer Ther. 2008, 7:3546-3555.
59. Younes M., Brown R.W., Mody D.R., Fernandez L., Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995, 15:2895-2898.
60. Younes M., Brown R.W., Stephenson M., Gondo M., Cagle P.T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 1997, 80:1046-1051.
61. Zamora-Leon S.P., Golde D.W., Concha, Rivas C.I., Delgado-Lopez F., Baselga J., Nualart F., Vera J.C. Expression of the fructose transporter GLUT5 in human breast cancer. Proc. Natl. Acad. Sci. USA 1996, 93:1847-1852.
62. Zhang J.Z., Behrooz A., Ismail-Beigi F. Regulation of glucose transport by hypoxia. Am. J. Kidney Dis. 1999, 34:189-202.